JPMorgan analyst Lisa Gill raised the firm’s price target on Privia Health (PRVA) to $32 from $29 and keeps an Overweight rating on the shares. The firm updated the company’s model.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PRVA:
- Privia Health price target raised to $24 from $23 at Barclays
- Privia Health Group Approves Key Proposals at Meeting
- Privia Health’s Earnings Call Highlights Growth and Challenges
- Privia Health Group’s Strong Performance and Strategic Expansion Drive Positive Outlook
- Privia Health Reports Strong Q1 2025 Results